Zai Lab/$ZLAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Ticker
$ZLAB
Sector
Primary listing
Employees
1,869
Headquarters
Website
Zai Lab Metrics
BasicAdvanced
$2.8B
-
-$2.03
1.03
-
Price and volume
Market cap
$2.8B
Beta
1.03
52-week high
$44.34
52-week low
$23.82
Average daily volume
677K
Financial strength
Current ratio
3.119
Quick ratio
2.508
Long term debt to equity
1.428
Total debt to equity
24.175
Interest coverage (TTM)
-60.26%
Profitability
EBITDA (TTM)
-233.854
Gross margin (TTM)
8.73%
Net profit margin (TTM)
-49.68%
Operating margin (TTM)
-57.73%
Revenue per employee (TTM)
$230,000
Management effectiveness
Return on assets (TTM)
-14.35%
Return on equity (TTM)
-28.41%
Valuation
Price to revenue (TTM)
6.187
Price to book
3.52
Price to tangible book (TTM)
3.8
Price to free cash flow (TTM)
-11.459
Free cash flow yield (TTM)
-8.73%
Free cash flow per share (TTM)
-2.21
Growth
Revenue change (TTM)
32.56%
Earnings per share change (TTM)
-33.76%
3-year revenue growth (CAGR)
32.92%
3-year earnings per share growth (CAGR)
-28.39%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Bulls say / Bears say
The FDA granted Fast Track designation to ZL-1310 in May 2025, accelerating its development and opening the path toward a pivotal trial and potential accelerated approval in 2027 (Business Wire)
At ASCO 2025, Zai Lab presented updated Phase 1a/1b results for ZL-1310 showing a 67% ORR across all doses (n=33) and 79% at 1.6 mg/kg (n=14) in second-line ES-SCLC, along with a favorable safety profile, supporting plans for a registrational study in H2 2025 (Nasdaq)
Total product revenue grew by 9% year over year to $110.0 million in Q2 2025, led by record VYVGART sales of $26.5 million—up 46% sequentially—showcasing solid commercial execution (Zai Lab Q2 2025 Release)
Q2 revenue of $110.0 million missed the analyst consensus of $124.95 million, causing a 9.7% pre-market drop and raising concerns about growth prospects (Investing.com)
ZEJULA sales dropped to $41.0 million in Q2 2025 from $45.0 million a year ago due to increased competition in the PARP inhibitor segment, putting pressure on a key revenue line (Zai Lab Q2 2025 Release)
Operating loss remained high at $54.9 million (GAAP) and $34.2 million (adjusted) in Q2 2025, with profitability now expected in Q4 2025, further extending the company’s cash burn risk (Zai Lab Q2 2025 Release)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study
Business Wire6 days ago
Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025
Business Wire2 weeks ago
Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $2.8B as of October 30, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of October 30, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of October 30, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.